

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>SIGMA PHARMACEUTICALS LIMITED</b>
<b>ABN</b>	<b>15 088 417 403</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Robert Hooper
<b>Date of last notice</b>	03/02/2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct								
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A								
<b>Date of change</b>	24/03/2017								
<b>No. of securities held prior to change</b>	<p>33,057,388</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%;">Ordinary Shares</td> <td style="text-align: right;">8,110,573</td> </tr> <tr> <td>Shares allocated pursuant to the employee share plan</td> <td style="text-align: right;">33,612</td> </tr> <tr> <td>Shares allocated pursuant to the loan funded long term incentive plan</td> <td style="text-align: right;">24,675,526</td> </tr> <tr> <td>Short term incentive plan performance rights</td> <td style="text-align: right;">237,677</td> </tr> </table>	Ordinary Shares	8,110,573	Shares allocated pursuant to the employee share plan	33,612	Shares allocated pursuant to the loan funded long term incentive plan	24,675,526	Short term incentive plan performance rights	237,677
Ordinary Shares	8,110,573								
Shares allocated pursuant to the employee share plan	33,612								
Shares allocated pursuant to the loan funded long term incentive plan	24,675,526								
Short term incentive plan performance rights	237,677								

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Ordinary
<b>Number acquired</b>	4,315,153
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$5,178,183.60
<b>No. of securities held after change</b>	37,372,541  Ordinary Shares 8,348,250  Shares allocated pursuant to the employee share plan 33,612  Shares allocated pursuant to the loan funded long term incentive plan 28,990,679  Short term incentive plan performance rights 0
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	4,315,153 shares allocated pursuant to Sigma's loan funded long term incentive plan.  The performance conditions will be tested at the end of the performance period (31/01/2020).  Performance conditions under the short term incentive plan were met and 237,677 performance rights converted to ordinary shares.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.